Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GPR6 | P46095 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SPR | P35270 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1447243 | 0.85 | POLB (0.57) | HPGDHTTGPR6TSHRPOLB | |
| SCHEMBL256310 | 0.84 | HPGD (0.59) | HPGDHTTTSHRPOLBNPC1 | |
| SCHEMBL4243617 | 0.84 | HTT (0.58) | HPGDHTTTSHRPOLBNPC1 | |
| SCHEMBL2104229 | 0.83 | HPGD (0.59) | HPGDHTTTSHRNPC1RAB9A | |
| SCHEMBL2799115 | 0.82 | DGAT1 (0.49) | HPGDTSHRNPC1RAB9AGAA | |
| SCHEMBL19086436 | 0.82 | HTT (0.47) | HPGDHTTGPR6TSHRPOLB | |
| SCHEMBL970089 | 0.81 | HPGD (0.55) | HPGDHTTPOLBRAB9AGAA | |
| SCHEMBL19869975 | 0.81 | RXFP1 (0.48) | HPGDHTTGPR6TSHRHRH4 | |
| SCHEMBL16098874 | 0.81 | HPGD (0.54) | HPGDHTTGPR6TSHRGAA | |
| SCHEMBL1447805 | 0.80 | POLB (0.68) | HPGDHTTTSHRPOLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10059705-B2 | Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-08-28 | — | — | US | disclosed |
| EP-2976341-B1 | ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-02-28 | — | — | EP | disclosed |
| EP-2976341-B1 | ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20160272634-A1 | ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160272634-A1 | ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160272634-A1 | ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-09-22 | — | — | US | disclosed |
| WO-2014146493-A1 | ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272634-A1 | ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | JAK1, JAK2, JAK3 | HPGD 798/4885HTT 4814/4885GPR6 1309/4885 |
| US-10059705-B2 | Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors | JAK1, JAK2, JAK3 | HPGD 798/4885HTT 4814/4885GPR6 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.